Cover Image

Personalized epigenetics /

Show other versions (1)

Personalized Epigenetics, Second Edition discusses the core translatability of epigenetics to health management of individuals who have unique variations in their epigenetic signatures that can guide both disorder and disease prevention and therapy. Fully updated and revised, this new edition detail...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Tollefsbol, Trygve O. (Editor)
Format: eBook
Language:English
Published: London, United Kingdom : Academic Press, 2024.
Edition:Second edition.
Series:Translational epigenetics series.
Subjects:
Epigenetics.
Épigénétique.
Epigenetics
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Intro
  • Personalized Epigenetics
  • Copyright
  • Contents
  • Contributors
  • Preface
  • Section I: Introduction
  • Chapter 1: Epigenetics of personalized medicine
  • 1. Introduction
  • 2. Epigenetic variations among individuals
  • 3. Technologies for personalized epigenetics
  • 4. Diagnostic and prognostic epigenetic approaches to personalized medicine
  • 5. Environmental personalized epigenetics
  • 6. Pharmacology and drug development of personalized epigenetics
  • 7. Personalized epigenetics of obesity and diabetes
  • 8. Personalized epigenetics of cancer
  • 9. Personalized epigenetics of neurological disorders and diseases
  • 10. Personalized epigenetics of other disorders and diseases
  • 11. Personalized epigenetics of pain management
  • 12. Challenges and future directions
  • 13. Conclusion
  • References
  • Section II: Epigenetic variations among individuals
  • Chapter 2: Personalized epigenetics: Analysis and interpretation of DNA methylation variation
  • 1. Introduction
  • 2. DNA methylation and demethylation mechanisms
  • 3. Genetic and epigenetic variations
  • 4. Allelic-specific DNA methylation
  • 5. Blood cellular heterogeneity and methylation variation
  • 6. Brain cellular heterogeneity and methylation variation
  • 7. Stem cellular heterogeneity and methylation variation
  • 8. Quantitative assessment of DNA methylation variation
  • 9. Closing remarks
  • References
  • Chapter 3: Differences in histone modifications between individuals
  • 1. Introduction
  • 2. Chromatin structure and histone modifications
  • 3. Analytical toolboxes for chromatin structure and histone modifications
  • 4. Copy number variations, quantitative trait loci, and single-nucleotide polymorphisms influence histone modifications
  • 5. The exposome
  • Different exposures induce differential modification of histones
  • 5.1. Airborne particulate matter exposure.
  • 5.2. Alcohol exposure
  • 5.3. Contaminated water exposure
  • 5.4. In utero exposure
  • 5.5. Occupational exposure
  • 5.6. Infectious exposure
  • 5.7. Nutritional exposure
  • 5.8. Plastic exposure
  • 5.9. Spaceflight exposure
  • 6. The metabolome: Differential metabolism and its influence on differential modifications of histones
  • 6.1. Diabetes
  • 6.2. Obesity
  • 7. Interactive effects of the exposome and metabolome on histone modifications
  • 8. Prospects for the analysis of histone modifications in humans
  • 9. Conclusion
  • References
  • Chapter 4: Individual noncoding RNA variations: Their role in shaping and maintaining the epigenetic landscape
  • 1. Introduction
  • 2. Regulatory interactions between microRNAs and epigenetic machinery
  • 2.1. Epigenetic modifications that affect the expression of microRNAs under neurodegenerative conditions
  • 2.1.1. MicroRNAs in Alzheimer's disease
  • 2.1.2. MicroRNAs in Parkinson's disease
  • 2.1.3. MicroRNAs in Huntington's disease
  • 2.2. Epigenetic modifications that affect microRNA expression in cancer
  • 2.2.1. Epigenetic drugs and regulation of microRNA expression in cancer cell lines
  • 2.2.1.1. Reexpression of miR-127 in bladder cancer cell lines
  • 2.2.1.2. Reexpression of miR-9 and miR-124 in cell lines from cancer models
  • 2.2.1.3. Reexpression of miR-34 family members in cell lines from cancer models
  • 2.2.1.4. Epigenetic modifications that increase expression of tumorigenic microRNAs
  • 2.2.2. Epigenetic modifications on genomic regions around microRNA loci in tumor tissues
  • 2.2.2.1. Transcriptional and epigenetic regulation of miR-200 family members in breast cancer
  • 2.2.2.2. Epigenetic signatures for prognosis in solid and hematological tumors
  • 3. MicroRNA-mediated regulation of epigenetic machinery
  • 3.1. miR-29 family members regulate DNMT3 expression.
  • 3.2. miR-22 regulates ten-eleven translocation-2 expression
  • 3.3. miR-34 regulates HDAC1 expression
  • 4. Epigenetic alterations and regulation of trinucleotide repeats in neurodegenerative diseases
  • 4.1. Evidence for toxic noncoding RNAs as drivers in trinucleotide repeat expansion disease
  • 4.2. Mechanisms of trinucleotide repeat expansion pathogenicity
  • 4.2.1. RNA hairpins
  • 4.2.2. Protein sequestration
  • 4.2.3. RNA/DNA duplexes
  • 4.2.4. Antisense transcription
  • 5. Long noncoding RNAs guide the epigenetic machinery and interfere with other noncoding RNA functions to regulate gene e ...
  • 5.1. Paradigms of long noncoding RNA function in the regulation of gene expression
  • 5.1.1. Long noncoding RNAs as guides for the epigenetic machinery
  • 5.1.2. Long noncoding RNA interferes with other noncoding RNA functions
  • 5.2. Long noncoding RNAs are associated with disease risk
  • 6. Conclusion
  • 6.1. MicroRNA biomarkers
  • 6.2. Trinucleotide repeat biomarkers
  • 6.3. Long noncoding RNA biomarkers
  • References
  • Section III: Technologies for personalized epigenetics
  • Chapter 5: Epigenetics technologies for personalized medicine
  • 1. Introduction
  • 2. Higher-order chromosomal structure profiling platforms
  • 3. CRISPR-based epigenetic modification
  • 4. Epigenetics and personalized therapies
  • 5. Epigenetic applications in personalized medicine
  • 5.1. Epigenetic biomarkers of disease
  • 5.2. Epigenetic drugs
  • 5.3. Epigenetic biomarkers of drug response
  • 5.4. Conclusion
  • 6. Current personalized medicines
  • 7. Challenges and future directions
  • 7.1. Challenges
  • 7.2. Future directions
  • References
  • Chapter 6: Computational methods in epigenetics
  • 1. Introduction
  • 2. Before you begin
  • 3. Key resources table
  • 4. Step-by-step method details
  • 4.1. Preprocessing
  • 4.2. Alignment
  • 4.3. Methylation calling.
  • 4.4. Differential methylation
  • 4.5. Annotation
  • 4.6. Integration with other molecular data
  • 5. Expected outcomes
  • 5.1. Differentially methylated sites/genes/regions
  • 5.2. Functional impact
  • 5.3. Integrated models
  • 6. Quantification and statistical analysis
  • 6.1. DMS/DMR
  • 6.2. DHR
  • 7. Advantages
  • 8. Limitations
  • 9. Optimization and troubleshooting
  • 10. Safety considerations and standards
  • References
  • Section IV: Diagnostic and prognostic epigenetic approaches to personalized medicine
  • Chapter 7: Epigenetic biomarkers in personalized medicine
  • 1. Introduction
  • 2. Cancer
  • 2.1. Hematological malignancies
  • 2.2. Solid tumors
  • 2.2.1. Colorectal cancer
  • 2.2.2. Gastric cancer
  • 2.2.3. Breast and ovarian cancer
  • 2.2.4. Prostate cancer
  • 2.2.5. Bladder cancer
  • 2.2.6. Lung cancer
  • 2.2.7. Other cancers
  • 2.2.8. Multicancer early detection and cancer of unknown primary origin epigenetic tests
  • 3. Noncancerous diseases
  • 3.1. Neurodegenerative diseases
  • 3.2. Psychiatric and behavioral disorders
  • 3.3. Autoimmune diseases
  • 3.4. Cardiovascular diseases
  • 3.5. Metabolic diseases
  • 3.6. Subfertility and assisted reproduction
  • 4. Concluding remarks
  • References
  • Chapter 8: Forensic epigenetics in the massively parallel sequencing era
  • 1. Introduction
  • 2. Analytical approaches in forensic epigenetics
  • 3. Fluid and tissue identification
  • 4. Epigenetic age prediction
  • 5. Monozygotic twins
  • 6. Lifestyle
  • 7. Pollution and location
  • 8. Conclusion
  • Acknowledgments
  • References
  • Chapter 9: Epigenetics in personalized toxicity
  • 1. Foreword
  • 2. Introduction to personalized toxicity
  • 3. Role of epigenetics in personalized toxicity
  • 4. Epigenetic variations and adverse drug response
  • 5. Epigenetic mechanisms underlying differential susceptibility to toxicity
  • 5.1. Nutrition.
  • 5.2. Environmental chemicals
  • 5.3. Compounds of abuse
  • 6. Integration of epigenetic analysis in toxicology
  • 7. Analytics beyond sequencing: Mass spectrometry in epigenetics
  • 7.1. The untargeted nature of mass spectrometry
  • 7.2. The complexity of the histone code
  • 7.3. Two complementary views on the histone code
  • 7.4. MS data acquisition and analysis
  • 8. Conclusions and future perspectives
  • References
  • Section V: Environmental personalized epigenetics
  • Chapter 10: Environmental contaminants and the epigenome
  • 1. Introduction
  • 2. Overview of epigenetic mechanisms and methods for assessment
  • 3. Inorganic metals and the epigenome
  • 3.1. Inorganic arsenic
  • 3.2. Cadmium
  • 3.3. Lead
  • 3.4. Chromium, mercury, and nickel
  • 4. Complex mixtures
  • 4.1. Cigarette smoke
  • 4.2. Air pollution-Associated chemicals and the epigenome
  • 5. Further considerations
  • References
  • Chapter 11: Nutriepigenomics: Paving the way for personalized nutrition
  • 1. Introduction
  • 2. Connection between chromatin structure and metabolic status
  • 2.1. Epigenetic modifications as a roadmap of the genomic landscape
  • 2.2. Development and disease dictated by epigenetic modifications
  • 2.3. Individual differences reflected in epigenetic patterns
  • 2.4. Nutrients and their metabolites that shape the epigenetic landscape
  • 3. Evidence for dietary factors affecting epigenetic patterns
  • 3.1. Diet compositions and nutrients
  • 3.1.1. Malnutrition and calorie restriction
  • 3.1.2. High-fat diets
  • 3.1.3. Folate and other vitamin B compounds related to one-carbon metabolism
  • 3.1.4. Vitamin C and E
  • 3.2. Bioactive food compounds
  • 3.2.1. Epigallocatechin gallate
  • 3.2.2. Genistein
  • 3.2.3. Quercetin
  • 3.2.4. Resveratrol
  • 3.2.5. Ellagic acid
  • 3.2.6. Curcumin
  • 3.2.7. Sulforaphane.